Research

These are the studies that are currently active.  The studies take place at Nottingham Children's Hospital only unless specified otherwise. 

Roxadustat

A Phase 3, Open-label, uncontrolled ( no placebo) Study to Evaluate the

Activity, Safety, Pharmacokinetics and Pharmacodynamics of

Roxadustat for the Treatment of Anemia in Pediatric Participants

with Chronic Kidney Disease

Action3

 A pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) who are receiving an angiotensin II receptor blocker (ARB)

Belatacept

A Prospective, Open-label, Multicentre, Randomized Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Renal Allograft Recipients Aged 12 to Less Than 18 Years of Age to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications

**Empa-Kidney-Kids ( LifeArc Study)

A randomised, double-blind, placebo-controlled trial with an

open-label extension to assess the pharmacokinetics, safety, and

efficacy of empagliflozin tablets in paediatric patients with

chronic kidney disease (EMPA-KIDNEY® Kids)

The LifeArc-Kidney Research UK Centre for Rare Diseases - Kidney Research UK

NephroS

This study was set up in January 2010 to investigate Steroid Resistant Nephrotic Syndrome in children. Due to the success of the project, in January 2015, the research study expanded to include both adult and child patients with Idiopathic Nephrotic Syndrome. Due to the increased eligibility criteria the study was re-named NephroS (The National Study of Nephrotic Syndrome).

Protego TAK

A Phase 3, open-label, single-arm, repeated-dose study to evaluate the

safety and tolerability, pharmacokinetics, and antiviral activity of

maribavir for the treatment of cytomegalovirus (CMV) infection in

children and adolescents who have received a hematopoietic stem cell

transplant (HSCT) or a solid organ transplant (SOT)

RaDaR

This is a UK-wide registry of rare kidney diseases and is open for recruitment in most centres throughout EMEESY. 

The patient-facing side of RaDaR is called RareRenal and has its own website. 

ZOSTER-47

A Phase II, randomised, open-label, multicentre study to assess the, safety of a  paediatric Herpes Zoster vaccine when administered intramuscularly to immunocompromised paediatric renal transplant recipients from 1 to 17 years of age.